Showing results (341-350 of 662) with videos related to

Sort By:
Pageof 67
Oecologia|December 12, 2018
Cane toads (Rhinella marina) rely on water access, not drought tolerance, to invade xeric Australian environmentsGeorge A Brusch, Keith Christian, Greg P Brown, et al.
Green Chemistry : an International Journal and Green Chemistry Resource : GC|April 22, 2014
Zebrafish Assays as Developmental Toxicity Indicators in The Design of TAML Oxidation CatalystsLisa Truong, Matthew A Denardo, Soumen Kundu, et al.
Physiological and Biochemical Zoology : PBZ|October 26, 2017
Hydric "Costs" of Reproduction: Pregnancy Increases Evaporative Water Loss in the Snake Vipera aspisOlivier Lourdais, Andréaz Dupoué, Michaël Guillon, et al.
Surgical and Radiologic Anatomy : SRA|July 20, 2011
Persistence of the otic artery with neurological sequelae: case reportR Shane Tubbs, Martin M Mortazavi, Andrew J Denardo, et al.
Global Public Health|December 8, 2020
The end of AIDS? HIV and the new landscape of illness in rural South AfricaSanyu A Mojola, Nicole Angotti, Danielle Denardo, et al.
Interventional Neuroradiology : Journal of Peritherapeutic Neuroradiology, Surgical Procedures and Related Neurosciences|November 11, 2022
Technical video: Onyx-18 embolization of spinal epidural arteriovenous Fistula using the scepter-Mini balloon catheterKrishna Amuluru, Andrew Denardo, John Scott, et al.
Cancer Research|December 1, 1995
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expressionS J DeNardo, P H Gumerlock, M D Winthrop, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenograftsG L DeNardo, L A Kroger, C F Meares, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 1998
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenograftsS J DeNardo, D L Kukis, L A Miers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RITSally J DeNardo, Gerald L DeNardo, A Yuan, et al.
Pageof 67